28.05.2019 • NewsBoehringer IngelheimDede Willams

Boehringer Ingelheim Expanding in Mexico

Boehringer Ingelheim Expanding in Mexico (c) Boehringer Ingelheim
Boehringer Ingelheim Expanding in Mexico (c) Boehringer Ingelheim

German drugmaker Boehringer Ingelheim is planning to invest around 1.6 billion pesos (about $84 million) at its three manufacturing sites in Mexico over the next two years, with the aim of boosting production at all three.

The first and biggest project with be to lift output at its Xochimilco tableting site for diabetic drugs near Mexico City, taking output capability to 2.5 billion tablets annually in 2028 from about 1.6 billion units currently.

 Boehringer said the expansion will allow it to increase exports to the US as well as Argentina, Colombia and Brazil.  

Last year, the drugmaker began construction on a $100 million R&D and manufacturing facility in Germany, where it plans to develop and manufacture more complex tablets for global launches. Simultaneously, it is moving production of what it calls older, less complex drugs to other worldwide sites.

 

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.